Diligence memo · auto-generated · as of July 2, 2026

Artificial Intelligence Medical Services, Inc.

Artificial Intelligence Medical Services, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

Artificial Intelligence Medical Services, Inc. operates in Biotechnology, based in SUWANEE.

Sub-sector tags: ai/ml.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Artificial Intelligence Medical Services, Inc. has raised $525K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $425K on 2021-03-01.

Most recent recorded round closed around 2023-08-14.

Valuation (modeled)modeled

Provath models Artificial Intelligence Medical Services, Inc. at approximately $798K (range $53K–$3.5M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.25× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era. Issuer reports $0–$1M revenue while modeled below niche peers.

Financing rhythm & timingmixed

Historic cadence: a new round about every 10 months.

Last raise 2.9 yr ago; this sector typically re-raises about every 14 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round was 2.0× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 12% of Biotechnology peers (4293 compared).

Modeled value ranks above 2% of those peers.

Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.